Mitochondria-tau association promotes cognitive decline and hippocampal bioenergetic deficits during the aging
- PMID: 38552927
- DOI: 10.1016/j.freeradbiomed.2024.03.017
Mitochondria-tau association promotes cognitive decline and hippocampal bioenergetic deficits during the aging
Abstract
Current studies indicate that pathological modifications of tau are associated with mitochondrial dysfunction, synaptic failure, and cognitive decline in neurological disorders and aging. We previously showed that caspase-3 cleaved tau, a relevant tau form in Alzheimer's disease (AD), affects mitochondrial bioenergetics, dynamics and synaptic plasticity by the opening of mitochondrial permeability transition pore (mPTP). Also, genetic ablation of tau promotes mitochondrial function boost and increased cognitive capacities in aging mice. However, the mechanisms and relevance of these alterations for the cognitive and mitochondrial abnormalities during aging, which is the primary risk factor for AD, has not been explored. Therefore, in this study we used aging C57BL/6 mice (2-15 and 28-month-old) to evaluate hippocampus-dependent cognitive performance and mitochondrial function. Behavioral tests revealed that aged mice (15 and 28-month-old) showed a reduced cognitive performance compared to young mice (2 month). Concomitantly, isolated hippocampal mitochondria of aged mice showed a significant decrease in bioenergetic-related functions including increases in reactive oxygen species (ROS), mitochondrial depolarization, ATP decreases, and calcium handling defects. Importantly, full-length and caspase-3 cleaved tau were preferentially present in mitochondrial fractions of 15 and 28-month-old mice. Also, aged mice (15 and 28-month-old) showed an increase in cyclophilin D (CypD), the principal regulator of mPTP opening, and a decrease in Opa-1 mitochondrial localization, indicating a possible defect in mitochondrial dynamics. Importantly, we corroborated these findings in immortalized cortical neurons expressing mitochondrial targeted full-length (GFP-T4-OMP25) and caspase-3 cleaved tau (GFP-T4C3-OMP25) which resulted in increased ROS levels and mitochondrial fragmentation, along with a decrease in Opa-1 protein expression. These results suggest that tau associates with mitochondria and this binding increases during aging. This connection may contribute to defects in mitochondrial bioenergetics and dynamics which later may conduce to cognitive decline present during aging.
Keywords: Aging; Mitochondria; Mitochondrial permeability transition pore (mPTP); Synaptic loss; Tau.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest All authors declare that they do not have any competing interests concerning this work and do not intend to pursue any such interests in the future.
Similar articles
-
Cyclophilin D (CypD) ablation prevents neurodegeneration and cognitive damage induced by caspase-3 cleaved tau.Free Radic Biol Med. 2025 May;232:128-141. doi: 10.1016/j.freeradbiomed.2025.02.035. Epub 2025 Feb 27. Free Radic Biol Med. 2025. PMID: 40023297
-
Cyclosporine A (CsA) prevents synaptic impairment caused by truncated tau by caspase-3.Mol Cell Neurosci. 2023 Jun;125:103861. doi: 10.1016/j.mcn.2023.103861. Epub 2023 May 12. Mol Cell Neurosci. 2023. PMID: 37182572
-
Caspase-3 cleaved tau impairs mitochondrial function through the opening of the mitochondrial permeability transition pore.Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166898. doi: 10.1016/j.bbadis.2023.166898. Epub 2023 Sep 28. Biochim Biophys Acta Mol Basis Dis. 2024. PMID: 37774936 Free PMC article.
-
The Role of Mitochondrial Impairment in Alzheimer´s Disease Neurodegeneration: The Tau Connection.Curr Neuropharmacol. 2020;18(11):1076-1091. doi: 10.2174/1570159X18666200525020259. Curr Neuropharmacol. 2020. PMID: 32448104 Free PMC article. Review.
-
Understanding the neuronal synapse and challenges associated with the mitochondrial dysfunction in mild cognitive impairment and Alzheimer's disease.Mitochondrion. 2023 Nov;73:19-29. doi: 10.1016/j.mito.2023.09.003. Epub 2023 Sep 13. Mitochondrion. 2023. PMID: 37708950 Review.
Cited by
-
Bioenergetic failure and oxidative stress: mitochondrial contributions to Alzheimer's disease.Inflammopharmacology. 2025 Aug 27. doi: 10.1007/s10787-025-01916-6. Online ahead of print. Inflammopharmacology. 2025. PMID: 40864415 Review.
-
The dopaminergic system and Alzheimer's disease.Neural Regen Res. 2025 Sep 1;20(9):2495-2512. doi: 10.4103/NRR.NRR-D-24-00230. Epub 2024 Sep 24. Neural Regen Res. 2025. PMID: 39314145 Free PMC article.
-
The role of Foxo3a in neuron-mediated cognitive impairment.Front Mol Neurosci. 2024 Jun 19;17:1424561. doi: 10.3389/fnmol.2024.1424561. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38962803 Free PMC article. Review.
-
Do Sex and Gender Interact with the Biological Actions of Taurine? A Critical Rereading of the Literature.Int J Mol Sci. 2025 Aug 21;26(16):8097. doi: 10.3390/ijms26168097. Int J Mol Sci. 2025. PMID: 40869416 Free PMC article. Review.
-
P2RX7 regulates tauopathy progression via tau and mitochondria loading in extracellular vesicles.Res Sq [Preprint]. 2025 Jun 23:rs.3.rs-6771517. doi: 10.21203/rs.3.rs-6771517/v1. Res Sq. 2025. PMID: 40678243 Free PMC article. Preprint.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials